Discontinuing febuxostat might cause more deaths than continuing febuxostat: the untold story from the CARES trial

Rheumatology (Oxford). 2020 Jun 1;59(6):1439-1440. doi: 10.1093/rheumatology/kez552.

Authors

Byeongzu Ghang^{1

2}, Soo Min Ahn¹, Jinseok Kim², Yong-Gil Kim¹, Chang-Keun Lee¹, Bin Yoo¹

Affiliations

¹ Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul.
² Division of Rheumatology, Department of Internal Medicine, Jeju National University School of Medicine, Jeju National University Hospital, Jeju, Korea.

PMID: 31748801
DOI: 10.1093/rheumatology/kez552

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Allopurinol / adverse effects
Cardiovascular Diseases / chemically induced
Cardiovascular Diseases / mortality*
Cause of Death
Febuxostat / adverse effects*
Female
Gout / drug therapy
Gout / mortality*
Gout Suppressants / adverse effects*
Humans
Male
Middle Aged
Randomized Controlled Trials as Topic
Substance Withdrawal Syndrome / mortality*
Withholding Treatment

Substances

Gout Suppressants
Febuxostat
Allopurinol